Shundong Cang

7.2k total citations · 1 hit paper
80 papers, 2.3k citations indexed

About

Shundong Cang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Shundong Cang has authored 80 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 32 papers in Molecular Biology. Recurrent topics in Shundong Cang's work include Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Colorectal Cancer Treatments and Studies (12 papers). Shundong Cang is often cited by papers focused on Lung Cancer Treatments and Mutations (21 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Colorectal Cancer Treatments and Studies (12 papers). Shundong Cang collaborates with scholars based in China, United States and Australia. Shundong Cang's co-authors include Delong Liu, Yuehua Ma, Shuhang Wang, Jiahuai Tan, Richard Petrillo, Chaitanya Iragavarapu, Zhiyu Song, Gang Jia, Peizhi Ma and Yongping Song and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Shundong Cang

78 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis

2021 204 citations Shundong Cang et al. profile →

Peers

Shundong Cang

ONCOL

PRM

PFM

Cornelia Quadt Switzerland

Silvia La Monica Italy

Antonella Papa United States

Josef Brueggen Switzerland

Matthew Squires United States

Alan Huang United States

Lisa Drew United States

Giulio Francia United States

Ben Markman Australia

Yongping Song China

Cornelia Quadt Switzerland

Shundong Cang

1.4k ×1.0

756 ×1.0

ONCOL

591 ×0.9

PRM

273 ×0.6

208 ×0.9

PFM

Citations per year, relative to Shundong Cang Shundong Cang (= 1×) peers Cornelia Quadt

Countries citing papers authored by Shundong Cang

Since Specialization

Citations

This map shows the geographic impact of Shundong Cang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shundong Cang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shundong Cang more than expected).

Fields of papers citing papers by Shundong Cang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shundong Cang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shundong Cang. The network helps show where Shundong Cang may publish in the future.

Co-authorship network of co-authors of Shundong Cang

This figure shows the co-authorship network connecting the top 25 collaborators of Shundong Cang. A scholar is included among the top collaborators of Shundong Cang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shundong Cang. Shundong Cang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Huajun, Hai‐Yan Tu, Yanping Hu, et al.. (2025). A phase II trial of anlotinib plus EGFR-TKIs in advanced non-small cell lung cancer with gradual, oligo, or potential progression after EGFR-TKIs treatment (CTONG-1803/ALTER-L001). Journal of Hematology & Oncology. 18(1). 3–3. 3 indexed citations

Chang, Jenny C., Yan Guo, Wei Yuan, et al.. (2025). HLA‐DR⁺ Tumor Cells Show an Association with a Distinct Immune Microenvironment and CD8⁺ T‐Cell Exhaustion in HBV‐Associated Hepatocellular Carcinoma. Advanced Science. 12(30). e02979–e02979. 2 indexed citations

Wu, Lin, Yinghua Ji, Gongyan Chen, et al.. (2025). Efficacy and safety of limertinib versus gefitinib as first-line treatment for locally advanced or metastatic non-small-cell lung cancer with EGFR-sensitising mutation: a randomised, double-blind, double-dummy, phase 3 trial. The Lancet Respiratory Medicine. 13(8). 677–686. 2 indexed citations

Jiang, Chenyang, Hao Feng, Z. Y. Ren, et al.. (2024). hnRNPA1 promotes the metastasis and proliferation of gastric cancer cells through WISP2-guided Wnt/β-catenin signaling pathway. Discover Oncology. 15(1). 465–465. 2 indexed citations

Xing, Puyuan, Dongqing Lv, Weineng Feng, et al.. (2024). 677P Comparison of performance of MET amplification detection by FISH, NGS and ddPCR in EGFRm advanced NSCLC patients post first-line osimertinib treatment failure: Analysis from a prospective, multi-center study in China. Annals of Oncology. 35. S1658–S1658.

Sun, Hao, et al.. (2024). Targeting the CD47/SIRPα pathway in malignancies: recent progress, difficulties and future perspectives. Frontiers in Oncology. 14. 1378647–1378647. 20 indexed citations

Zhou, Qing, Jie Li, Shundong Cang, et al.. (2024). FLAIR: A Phase II, Open Label, Randomized Study of Osimertinib Plus Bevacizumab Versus Osimertinib in Recurrent or Metastatic Treatment-Naïve NSCLC Patients Harboring EGFR 21L858R Mutation. Clinical Lung Cancer. 26(2). 152–157.e1. 4 indexed citations

Feng, Hao, Z. Y. Ren, Xiang Li, et al.. (2023). SNHG3/WISP2 Axis Promotes Hela Cell Migration and InvasionviaActivating Wnt/β-Catenin Signaling. Cancer Genomics & Proteomics. 20(6suppl). 744–753. 2 indexed citations

Zhang, Li, Zhehai Wang, Jian Fang, et al.. (2022). Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 171. 56–60. 39 indexed citations

10.

Xu, Jianming, Hong Jiang, Yueyin Pan, et al.. (2021). LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study. Annals of Oncology. 32. S1331–S1331. 91 indexed citations

11.

Zhou, Caicun, Lin Wu, Yun Fan, et al.. (2020). LBA56 ORIENT-12: Sintilimab plus gemcitabine and platinum (GP) as first-line (1L) treatment for locally advanced or metastatic squamous non-small-cell lung cancer (sqNSCLC). Annals of Oncology. 31. S1186–S1186. 14 indexed citations

12.

Ren, Zhenggang, Jia Fan, Jian Xu, et al.. (2020). LBA2 Sintilimab plus bevacizumab biosimilar vs sorafenib as first-line treatment for advanced hepatocellular carcinoma (ORIENT-32)2. Annals of Oncology. 31. S1287–S1287. 25 indexed citations

13.

Zhu, Yanyan, Shundong Cang, Bowang Chen, et al.. (2020). Patient Stratification of Clear Cell Renal Cell Carcinoma Using the Global Transcription Factor Activity Landscape Derived From RNA-Seq Data. Frontiers in Oncology. 10. 526577–526577. 8 indexed citations

14.

Yang, Yunpeng, Zhaoguang Wang, Jian Fang, et al.. (2020). LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC). Annals of Oncology. 31. S1186–S1186. 1 indexed citations

15.

Fu, Lei, et al.. (2020). Knockdown of circular RNA circ-FARSA restricts colorectal cancer cell growth through regulation of miR-330-5p/LASP1 axis. Archives of Biochemistry and Biophysics. 689. 108434–108434. 32 indexed citations

16.

Zheng, Bowen, et al.. (2019). [Effect of omeprazole on plasma concentration and adverse reactions of capecitabine in patients with colon cancer].. PubMed. 41(9). 708–711. 5 indexed citations

17.

Cang, Shundong, et al.. (2015). ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. Journal of Hematology & Oncology. 8(1). 129–129. 221 indexed citations

18.

Liu, Katherine, Shundong Cang, Yuehua Ma, & Jen Wei Chiao. (2013). Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells. Cancer Cell International. 13(1). 10–10. 67 indexed citations

19.

Tan, Jiahuai, et al.. (2009). t(3;9;22) 3-Way Chromosome Translocation in Chronic Myeloid Leukemia is Associated with Poor Prognosis. Cancer Investigation. 27(7). 718–722. 5 indexed citations

20.

Lan, Yajia, et al.. (2000). [A cohort study on the relationship between vegetable intake and risks of lung cancer in the Tin Corporation (YTC) miners in Yunnan].. PubMed. 21(3). 205–7. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact